bivalirudin and Hemophilia-A

bivalirudin has been researched along with Hemophilia-A* in 3 studies

Reviews

1 review(s) available for bivalirudin and Hemophilia-A

Article	Year
Successful multi-vessel percutaneous coronary intervention with bivalirudin in a patient with severe hemophilia A: a case report and review of literature. The Journal of invasive cardiology, 2004, Volume: 16, Issue:6 We describe a 64-year-old male with severe hemophilia A (factor VIII-dependent), acute myocardial infarction (MI) and congestive heart failure (CHF) who underwent successful multi-vessel percutaneous coronary intervention (PCI). The patient was administered factor VIII transfusion to maintain activity levels between 60-80%. Anticoagulation during the PCI procedure was maintained with the direct thrombin inhibitor, bivalirudin. There were no procedural complications and the patient was discharged home the following day. These results suggest that bivalirudin may be used effectively in patients at very high risk of bleeding with enhanced procedural safety. Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Blood Component Transfusion; Coronary Angiography; Factor VIII; Hemophilia A; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Radiography, Interventional; Recombinant Proteins	2004

Article

Year

Successful multi-vessel percutaneous coronary intervention with bivalirudin in a patient with severe hemophilia A: a case report and review of literature.

The Journal of invasive cardiology, 2004, Volume: 16, Issue:6

We describe a 64-year-old male with severe hemophilia A (factor VIII-dependent), acute myocardial infarction (MI) and congestive heart failure (CHF) who underwent successful multi-vessel percutaneous coronary intervention (PCI). The patient was administered factor VIII transfusion to maintain activity levels between 60-80%. Anticoagulation during the PCI procedure was maintained with the direct thrombin inhibitor, bivalirudin. There were no procedural complications and the patient was discharged home the following day. These results suggest that bivalirudin may be used effectively in patients at very high risk of bleeding with enhanced procedural safety.

Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Blood Component Transfusion; Coronary Angiography; Factor VIII; Hemophilia A; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Radiography, Interventional; Recombinant Proteins

2004

Other Studies

2 other study(ies) available for bivalirudin and Hemophilia-A

Article	Year
Safety and Effectiveness of Bivalirudin for Perioperative Anticoagulation in a Patient With Hemophilia A Undergoing Percutaneous Coronary Intervention. The American journal of the medical sciences, 2021, Volume: 361, Issue:6 Topics: Aged; Anticoagulants; Hemophilia A; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Perioperative Care; Recombinant Proteins; Treatment Outcome	2021
Successful percutaneous coronary intervention in a patient with severe haemophilia A using bivalirudin as the sole procedural anticoagulant. Haemophilia : the official journal of the World Federation of Hemophilia, 2005, Volume: 11, Issue:4 This article presents the case of a patient with severe haemophilia A who underwent successful multivessel percutaneous coronary intervention (PCI). Patients with haemophilia who are diagnosed with coronary artery disease (CAD) and require intervention present a challenge to doctors due to the high risks of bleeding. The patient was administered recombinant factor VIII pre- and post-procedure. Anticoagulation during PCI was maintained with bivalirudin, a thrombin-specific anticoagulant. There were no complications and the patient tolerated the procedure well. This case suggests that bivalirudin as the sole procedural anticoagulant can be safely used in patients with a very high risk of bleeding undergoing PCI. Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Artery Disease; Hemophilia A; Hirudins; Humans; Intraoperative Care; Male; Middle Aged; Peptide Fragments; Recombinant Proteins; Treatment Outcome	2005

Article

Year

Safety and Effectiveness of Bivalirudin for Perioperative Anticoagulation in a Patient With Hemophilia A Undergoing Percutaneous Coronary Intervention.

The American journal of the medical sciences, 2021, Volume: 361, Issue:6

Topics: Aged; Anticoagulants; Hemophilia A; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Perioperative Care; Recombinant Proteins; Treatment Outcome

2021

Successful percutaneous coronary intervention in a patient with severe haemophilia A using bivalirudin as the sole procedural anticoagulant.

Haemophilia : the official journal of the World Federation of Hemophilia, 2005, Volume: 11, Issue:4

This article presents the case of a patient with severe haemophilia A who underwent successful multivessel percutaneous coronary intervention (PCI). Patients with haemophilia who are diagnosed with coronary artery disease (CAD) and require intervention present a challenge to doctors due to the high risks of bleeding. The patient was administered recombinant factor VIII pre- and post-procedure. Anticoagulation during PCI was maintained with bivalirudin, a thrombin-specific anticoagulant. There were no complications and the patient tolerated the procedure well. This case suggests that bivalirudin as the sole procedural anticoagulant can be safely used in patients with a very high risk of bleeding undergoing PCI.

Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Artery Disease; Hemophilia A; Hirudins; Humans; Intraoperative Care; Male; Middle Aged; Peptide Fragments; Recombinant Proteins; Treatment Outcome

2005